Among the peptide stacks gaining traction in UAE-based laboratory settings through mid-2026, the combination of retatrutide and NAD+ precursors stands out for a structurally sound reason: it addresses two distinct but mechanistically overlapping metabolic research axes within a single protocol design. Retatrutide works at the receptor level, modulating GIP, GLP-1, and glucagon signalling simultaneously. NAD+ precursor research operates deeper — at the mitochondrial and enzymatic level — through the sirtuin and PARP pathways that govern cellular energy maintenance, oxidative stress response, and metabolic gene expression.
The pairing is not intuitive at first glance. Retatrutide research is primarily framed around energy intake and expenditure modulation via receptor agonism. NAD+ research sits in the longevity and bioenergetics space. But the two converge meaningfully when researchers design protocols targeting adipose tissue dynamics, hepatic metabolism, and insulin sensitivity — all areas where both compounds have documented independent research interest, and all areas of particular relevance in the Gulf region, where the metabolic disease burden and corresponding research infrastructure are both substantial.
Research procurement data from REVIVE LAB UAE shows a consistent pattern through Q2 2026: retatrutide vials and NAD+ precursor compounds are increasingly being ordered together by lab teams based in Business Bay, Jumeirah Beach Residence (JBR), the Dubai Marina corridor, and academic-adjacent institutions in Sharjah and Abu Dhabi. The combination is not accidental. It reflects a deliberate protocol architecture — researchers are designing multi-axis metabolic studies rather than running siloed single-compound experiments, and they want compounds that produce overlapping but measurable independent effects.
This guide provides the analytical framework for that research design. It is not clinical guidance. It is a structured, opinionated reference for peptides-UAE researchers who are serious about building protocols that generate data worth publishing. Everything discussed here is for research-use only, in controlled laboratory settings.
Retatrutide is a synthetic peptide functioning as a unimolecular triple agonist at three distinct receptor targets: GIP (glucose-dependent insulinotropic polypeptide receptor), GLP-1 (glucagon-like peptide-1 receptor), and the glucagon receptor. This simultaneous triple-receptor engagement is what distinguishes it from its predecessor compound classes. Dual GLP-1/GIP agonists hit two axes; glucagon monoagonists hit one. Retatrutide activates all three, producing overlapping effects on hepatic glucose output, gastric motility, adipose energy mobilisation, and pancreatic function that are still being fully characterised across multiple research fronts.
The pivotal Phase 2 data, published by Jastreboff et al. in the New England Journal of Medicine (2023), established the dose-response relationship across a 48-week observation period and demonstrated that triple-receptor agonism produces effects meaningfully exceeding those attributed to any single-receptor target. The Eli Lilly TRIUMPH Phase 3 programme — currently in readout phase — is designed to confirm and extend these findings across larger cohorts and longer observation windows, with additional metabolic endpoints beyond body composition. Both datasets are essential reading for any researcher designing a retatrutide protocol in 2026.
For stack protocol design, the triple-agonism mechanism matters beyond the headline efficacy numbers. When you co-administer a second compound with retatrutide, you are not working alongside a clean single-pathway signal — you are working in the context of simultaneous GIP, GLP-1, and glucagon receptor activity. Any second compound whose mechanism intersects even partially with these pathways will produce interaction effects that need to be measured and interpreted, not assumed away. NAD+ precursors intersect through mitochondrial and hepatic metabolic pathways that retatrutide's glucagon receptor activity directly engages. That intersection is precisely what makes this stack scientifically interesting to study.
REVIVE LAB UAE supplies retatrutide as lyophilized research vials in two formats: 5mg and 10mg. In published and preprint research-context literature, titration frameworks reference starting ranges of approximately 2mg, with step-up increments toward 4mg and subsequently 8mg over multi-week observation windows. These ranges reflect the dose-response architecture documented in the Phase 2 data and provide a structured scaffold for experimental design. They are reference points for research protocol construction, not instructions for human use.
| Vial Format | Research Context Application | Reconstitution Standard | UAE Stock Status |
|---|---|---|---|
| Retatrutide 5mg | Lower titration range protocols (~2mg–4mg reference window), shorter observation periods | Bacteriostatic water; store at 2–8°C post-reconstitution | In stock — REVIVE LAB UAE |
| Retatrutide 10mg | Full titration range protocols (~2mg–8mg), multi-week studies, higher-frequency sampling | Bacteriostatic water; store at 2–8°C post-reconstitution | In stock — REVIVE LAB UAE |
NAD+ (nicotinamide adenine dinucleotide) is a co-enzyme present in every living cell, operating as an electron carrier in metabolic redox reactions and as a substrate for two critical enzyme families: sirtuins (SIRT1 through SIRT7) and PARPs (poly ADP-ribose polymerases). Both enzyme families compete for the same NAD+ pool — SIRT1 and SIRT3 directing metabolic gene expression and mitochondrial biogenesis, PARPs responding to DNA damage and oxidative stress. When cellular NAD+ is abundant, sirtuin activity is favoured. When NAD+ is depleted — as occurs with ageing, metabolic stress, and sustained oxidative load — PARP activation dominates and sirtuin-driven metabolic regulation declines.
Trammell et al. (2016, Nature Communications) established the foundational pharmacokinetic case for NAD+ precursor research. The study demonstrated that orally administered NR (nicotinamide riboside) significantly elevated the NAD+ metabolome in healthy human subjects, documenting measurable increases in NAD+ and its downstream metabolites — including NAAD and MeNAM — across blood compartments. This paper confirmed that exogenous NAD+ precursor administration is a viable and measurable intervention for researchers aiming to modulate cellular NAD+ availability. It remains the anchor citation for NAD+ precursor research design.
NMN (nicotinamide mononucleotide) functions as a more direct NAD+ precursor in the biosynthetic pathway and has attracted significant research interest since the Trammell et al. findings, though comparative pharmacokinetic data between NMN and NR in human subjects continues to develop. For research protocol design purposes, the key variable is NAD+ metabolome elevation — the specific precursor chosen should be determined by the availability of validated biomarkers and the specific pathway interaction being studied, not by marketing claims.
The research interest in NAD+ for metabolic co-intervention studies stems from three converging observations. First, SIRT1 and SIRT3 — the primary sirtuin targets of NAD+ — have well-characterised roles in fatty acid oxidation, mitochondrial biogenesis via PGC-1 alpha activation, and hepatic glucose regulation. Second, PARP1 activity — which competes with sirtuins for NAD+ — is elevated under oxidative stress conditions, which are precisely the conditions that metabolically challenged tissue models exhibit. Third, hepatic NAD+ availability modulates insulin sensitivity through SIRT1-mediated pathways, making it mechanistically adjacent to the glucagon receptor effects that retatrutide engages. These overlaps are not coincidental; they are the scientific basis for the stack.
The case for combining retatrutide with NAD+ precursor research in a single protocol is built on three mechanistic hypotheses. Each hypothesis is independently testable, and together they give the research design internal coherence. None of them constitutes a clinical claim. They are the analytical framework that makes this a productive stack to investigate — not evidence of efficacy for any therapeutic purpose.
Hypothesis one: glucagon receptor agonism amplifies hepatic NAD+ demand. Retatrutide's glucagon receptor activation stimulates hepatic energy expenditure through enhanced fatty acid oxidation. This is a metabolically intensive process that generates oxidative byproducts and places acute demands on mitochondrial NAD+ pools — specifically the NAD+:NADH ratio that drives the tricarboxylic acid cycle. If concurrent NAD+ precursor administration sustains or elevates hepatic NAD+ availability under these conditions, downstream SIRT1-mediated PGC-1 alpha activation could amplify the mitochondrial biogenesis signal beyond what glucagon receptor agonism alone achieves. Researchers designing hepatic metabolism studies have strong mechanistic grounds for including NAD+ precursor intervention as an active experimental variable, not a background condition.
Hypothesis two: GLP-1 receptor agonism and pancreatic NAD+ availability are not independent variables. GLP-1 receptor agonism has demonstrated effects on pancreatic beta-cell function and stress resilience in preclinical models. Beta-cell NAD+ levels are known to influence insulin secretion dynamics and cellular stress responses — depleted NAD+ in beta cells correlates with impaired function and heightened apoptotic susceptibility. Research protocols that pair retatrutide with NAD+ precursors can therefore probe whether NAD+ availability modulates, mediates, or is independent of the pancreatic effects attributed to GLP-1 receptor agonism. That is a publishable question.
Hypothesis three: caloric restriction states and exogenous NAD+ precursors may interact non-additively. Caloric restriction in preclinical models activates SIRT1 through increased NAD+:NADH ratios — a direct consequence of reduced caloric flux through metabolic pathways. If retatrutide-associated energy intake reduction in research models produces a comparable metabolic state, co-administration of NAD+ precursors raises the question of whether exogenous NAD+ elevation is additive, neutral, or even redundant in a model already experiencing SIRT1 activation through caloric flux reduction. That interaction question does not have a published answer. A well-designed UAE research protocol could generate one.
Structuring a retatrutide + NAD+ stack protocol requires decisions across three design dimensions: the retatrutide titration trajectory, the NAD+ precursor administration timing and compound selection, and the measurement panel that will allow meaningful interaction data to be extracted. The framework below is drawn from published research-context literature and is intended as a scaffold for UAE lab teams designing their own protocols — not as a fixed protocol or any form of clinical instruction.
Published preclinical and Phase 2 literature consistently references a step-up titration approach for retatrutide. In research protocol contexts, this translates to initiating at the lower end of the documented titration range (approximately 2mg equivalents), with incremental escalation toward the 4mg and then 8mg reference ranges over multi-week observation windows. The step-up architecture is not arbitrary — it reflects documented receptor adaptation dynamics and allows researchers to characterise threshold versus dose-dependent effects at each escalation point.
| Protocol Phase | Retatrutide Reference Range | NAD+ Precursor Timing | Primary Measurement Focus |
|---|---|---|---|
| Phase 1 — Weeks 1–4 | ~2mg titration range | Baseline NAD+ metabolome characterisation; precursor withheld | Receptor adaptation markers; baseline metabolic panel; plasma glucagon, GIP, GLP-1 dynamics |
| Phase 2 — Weeks 5–8 | ~4mg titration range | NAD+ precursor co-administration initiated | Hepatic enzyme panels (ALT, AST, GGT); plasma NAD+ metabolome; SIRT1/SIRT3 activity markers |
| Phase 3 — Weeks 9–12 | ~8mg titration range | Continued NAD+ precursor co-administration | Full metabolic panel; adipose tissue sampling; HOMA-IR equivalent; oxidative stress markers; sirtuin activity vs. baseline |
The delayed introduction of NAD+ precursor co-administration (beginning in Phase 2 rather than Phase 1) is deliberate. It allows Phase 1 data to establish a clean retatrutide-only baseline for the metabolic markers of interest, making Phase 2 and 3 interaction effects interpretable against a known single-compound trajectory. If both compounds are introduced simultaneously, the interaction cannot be disentangled from individual compound effects in retrospective analysis.
A retatrutide + NAD+ stack study generates useful data only if the measurement panel captures both compound-specific outputs and genuine interaction signals. Recommended research variable categories include:
The parallel tracking of the NAD+ metabolome alongside the glucagon/GIP/GLP-1 downstream markers is precisely what elevates this from two co-running single-compound studies to an interaction study. Without the combined measurement panel, you will capture individual compound effects but miss the mechanistic crosstalk — and the crosstalk is the finding that generates novel research value.
Procurement of research-grade peptides in the UAE has historically been fragmented. Cross-border cold-chain logistics into a desert climate, variable quality documentation standards, and inconsistent stock availability have forced many UAE research teams to accept compromises on sourcing quality or lead times. REVIVE LAB UAE was established specifically to close these gaps — operating as a domestic UAE supplier with locally held stock, eliminating the cold-chain transit risk inherent in international shipping to DXB and other UAE entry points.
REVIVE LAB UAE holds continuous stock of retatrutide in both 5mg and 10mg lyophilized research vial formats. Orders placed before 12:00 noon UAE time are dispatched same-day to Dubai addresses — covering JBR, Marina, Business Bay, DIFC, Downtown Dubai, Jumeirah, Palm Jumeirah, and Dubai Hills. The 24h delivery coverage extends to Abu Dhabi (including the Corniche research corridor and Khalifa City), Sharjah, Ajman, Ras Al Khaimah, and Fujairah. Researchers at institutions across all seven emirates have confirmed next-business-day receipt for afternoon-placed orders.
All REVIVE LAB UAE orders ship in discreet, unmarked packaging as an unconditional default — not an optional upgrade. Cash on delivery is available for Dubai orders for researchers who prefer not to pre-pay online for compound procurement. For larger institutional orders or researchers outside Dubai, Binance Pay (USDT TRC20) is available with a 5% pre-pay discount, making it cost-effective for labs placing multi-vial orders. Certificates of Analysis and HPLC purity documentation are available on request for all retatrutide vials — a non-negotiable requirement for any research team intending to publish findings or present to institutional review structures.
For peptides-Dubai and peptides-UAE research teams operating on publication timelines, the domestically held stock model matters beyond convenience. It eliminates the multi-week international procurement lead times that have historically disrupted UAE research schedules, and it means that cold-chain integrity is maintained for the entire supply chain — not just the final mile. REVIVE LAB UAE is the supplier of record for researchers who need retatrutide in stock UAE without compromise on quality documentation or delivery reliability.
Dubai's climate creates peptide storage challenges that researchers in temperate environments rarely confront. Ambient temperatures exceed 45°C in July and August, and even in air-conditioned research facilities, transition points — building entries, vehicle transport between labs, brief power interruptions — can expose compounds to elevated temperatures for short windows. For reconstituted peptide solutions, even brief thermal excursions can compromise stability. Lyophilized formats are considerably more tolerant of short ambient exposure, but controlled storage remains the research standard.
Retatrutide research vials in lyophilized form should be stored at 2°C to 8°C in a standard laboratory refrigerator, protected from light. Long-term storage at -20°C extends stability for studies where vials will not be used within weeks of receipt. Once reconstituted with bacteriostatic water, the resulting solution should be stored at 2°C to 8°C and used within a research-appropriate timeframe consistent with your institution's compound handling protocols. Repeated freeze-thaw cycling of reconstituted solutions is not recommended in any research context.
REVIVE LAB UAE dispatches retatrutide with cold packs and insulated packaging rated for UAE summer ambient temperatures, calibrated for the standard last-mile delivery window in Dubai and Abu Dhabi (typically one to three hours from dispatch to recipient). Researchers in locations with longer delivery windows — some Abu Dhabi addresses, northern emirates — should factor this into their order timing and consider requesting additional cold-pack insulation for high-summer orders. For NAD+ precursor compounds stored alongside retatrutide, note that NMN and NR in lyophilized or powder form are moisture-sensitive rather than primarily temperature-sensitive: coastal UAE locations including JBR, the Marina, and the Abu Dhabi Corniche present humidity challenges that require sealed, desiccant-containing storage even in air-conditioned environments.
Yes. REVIVE LAB UAE maintains domestic UAE stock of retatrutide 5mg and 10mg research vials and dispatches same-day for orders confirmed before 12:00 noon UAE time. Coverage includes all Dubai areas — JBR, Marina, Business Bay, DIFC, Downtown, Palm Jumeirah, Dubai Hills — as well as Abu Dhabi, Sharjah, and the wider UAE within a 24-hour window. Cash on delivery is available for Dubai orders as standard. All packaging is discreet with no compound identification on external labelling.
REVIVE LAB UAE carries retatrutide in 5mg and 10mg lyophilized research vials. The 5mg vial is suited to protocols operating in the 2mg–4mg titration reference range — shorter studies, lower-throughput research designs, or initial exploratory protocols. The 10mg vial is the preferred format for multi-week protocols covering the full 2mg–8mg titration range, where vial economy and consistency across the observation period matter. Both formats are supplied research-use only with Certificate of Analysis documentation available on request. Order at revivelab.ae/buy-retatrutide-uae/.
Yes. REVIVE LAB UAE ships retatrutide research vials to all seven emirates. Dubai researchers receive same-day dispatch on orders placed before noon; Abu Dhabi and Sharjah researchers typically receive orders within 24 hours of dispatch. Institutional orders from universities, private research facilities, and corporate R&D labs across the UAE are supported — REVIVE LAB UAE provides bulk pricing and comprehensive documentation packages including CoA and HPLC data for institutional procurement. Contact REVIVE LAB UAE directly through revivelab.ae for institutional enquiries.